We found that all 14 reagents detected Tau lesions in all three tauopathies, thus establishing these reagents’ ability to detect pathological Tau in clinically relevant samples where the protein is present in disease-specific conformational folds and aggregation states. This evidence concerns the gene MAPT and tauopathy.